Recommended Chemotherapy for Concurrent Chemoradiation in Head and Neck Cancer
High-dose cisplatin at 100 mg/m² administered intravenously every 3 weeks (on days 1,22, and 43) is the preferred Category 1 chemotherapy regimen for concurrent chemoradiation therapy in head and neck cancer. 1
Primary Treatment Setting (Definitive CCRT)
Single-agent cisplatin 100 mg/m² every 3 weeks is the standard regimen for patients receiving definitive concurrent chemoradiation, delivering 2-3 cycles depending on the radiation fractionation scheme (typically 70 Gy in 7 weeks at 2.0 Gy/fraction). 1, 2
- This regimen achieved superior laryngeal preservation rates (88% at 2 years) compared to induction chemotherapy (74%) or radiation alone (69%) in the landmark RTOG 91-11 trial, with sustained benefit at 10-year follow-up. 1
- The regimen is specifically recommended for locally advanced disease including T3-T4 tumors and N2-N3 nodal involvement. 1, 2
- IMRT is the preferred radiation technique to minimize dose to critical structures (salivary glands, temporal lobes, auditory structures). 2, 3
Postoperative Setting (Adjuvant CCRT)
Concurrent single-agent cisplatin at 100 mg/m² every 3 weeks for 3 doses is recommended for high-risk postoperative patients with extracapsular nodal extension and/or positive surgical margins. 4, 1, 4
- This recommendation is based on two pivotal trials (EORTC 22931 and RTOG 9501) demonstrating improved locoregional control and survival with postoperative chemoradiation versus radiation alone. 1, 2
- Radiation dose is typically 60-66 Gy at 2.0 Gy/fraction to high-risk regions. 3
- Treatment should begin as soon as possible after surgery, ideally within 6 weeks. 3, 5
Alternative Regimens
While other regimens exist, they are not preferred:
- Weekly cisplatin (40 mg/m² weekly): Increasingly used in practice with emerging evidence of non-inferiority for disease outcomes and reduced toxicity. 6, 7 However, this lacks the robust prospective validation of the three-weekly regimen and is not designated as Category 1 by NCCN guidelines. 1
- Carboplatin plus 5-FU: The GORTEC 99-02 trial used standard fractionation plus 3 cycles of carboplatin/5-FU, showing efficacy. 1 However, cisplatin remains preferred due to superior activity. 8
- Cetuximab: FDA-approved for combination with radiation in locally advanced SCCHN, but not considered equivalent to cisplatin-based regimens for most patients. 9
Critical Implementation Considerations
Cumulative cisplatin dose threshold: A minimum cumulative dose of 200 mg/m² is generally regarded as necessary for beneficial anti-tumor effect. 6, 8 Approximately 40% of patients fail to receive all three cycles of high-dose cisplatin, making compliance monitoring essential. 6
Toxicity profile: High-dose cisplatin carries significant toxicity burden including:
- Grade 3/4 mucositis (33%), dermatitis (41%), dysphagia (15%) 7
- Hematologic suppression, renal impairment (3%), nausea/vomiting 7, 10
- Cardiopulmonary arrest risk requiring electrolyte monitoring (magnesium, potassium, calcium) 9
- Treatment-related mortality (reported 3/30 patients in stage IV disease) 10
Patient selection is critical: Not all patients can tolerate concurrent therapy. 2 Stage IV unresectable disease showed particularly high toxicity rates with prolonged treatment times (median 63 days) and frequent treatment breaks. 10 Aggressive supportive care including antiemetics, hydration, nutritional support, and close monitoring is mandatory. 1, 2
Common Pitfalls to Avoid
- Inadequate supportive care: Chemoradiation requires an experienced multidisciplinary team with substantial supportive care infrastructure. 4, 1, 4
- Dose reductions without cause: Maintain the 100 mg/m² dose unless specific toxicities mandate reduction per protocol. 1
- Delayed treatment initiation: In the postoperative setting, delays beyond 6 weeks compromise outcomes. 3, 5
- Ignoring cumulative dose: If a patient cannot complete at least 200 mg/m² cumulative cisplatin, consider alternative strategies early. 6, 8